普瑞巴林治疗原发性舌咽神经痛的疗效观察

潘建+吴定芬+徐浩

[摘要] 目的 探讨普瑞巴林治疗原发性舌咽神经痛的临床疗效和安全性。 方法 选取2014年6月～2016年6月镇海龙赛医院口腔科70例舌咽神经痛患者，随机分为实验组和对照组，每组各35例，实验组、对照组分别给予普瑞巴林、卡马西平治疗。比较两组在4周后的疗效和不良反应发生情况。结果 实验组药物治疗有效率为74.3%，对照组药物治疗有效率为60.0%，两组比较，差异具有统计学意义（P<0.05）。与治疗前相比，两组患者的发作次数、疼痛持续时间及疼痛程度均有不同程度地下降。治疗后，实验组的发作次数、疼痛持续时间及疼痛程度（VAS评分）较对照组明显下降，两组比较差异有统计学意义（P<0.05）。实验组的不良反应发生率低于对照组。结论 普瑞巴林治疗舌咽神经痛疗效确切，安全可靠，值得临床推广和应用。

[关键词] 舌咽神经痛；普瑞巴林；安全性；不良反应

[中图分类号] R741 [文献标识码] B [文章编号] 1673-9701（2017）22-0067-03

[Abstract] Objective To evaluate the clinical efficacy and safety of pregabalin in the treatment of primary glossopharyngeal neuralgia. Methods A total of 70 patients with glossopharyngeal neuralgia in department of stomatology of Zhenhai Longsai Hospital from June 2014 to June 2016 were randomly divided into experimental group and control group， with 35 cases in each group. The experimental group was given pregabalin treatment， and the control group was given carbamazepine treatment. The efficacy and adverse events between the two groups were compared after 4 weeks. Results The effective rate of drug treatment was 74.3% in the experimental group and 60.0% in the control group. The difference between the two groups was statistically significant（P<0.05）. Compared with before treatment， the number of attacks， duration of pain and pain levels after treatment had varying degrees of decline in the two groups of patients. After treatment， the number of attacks， pain duration and pain level（VAS score） in the experimental group decreased significantly compared with those of the control group， and the difference was statistically significant（P<0.05）. The incidence of adverse reactions in the experimental group was lower than that in the control group. Conclusion Pregabalin is effective and safe in the treatment of glossopharyngeal neuralgia，which is worthy of population and application.

[Key words] Gglossopharyngeal neuralgia； Pregabalin； Safety； Adverse reactions

舌咽神经痛是一种出现于舌咽神经分部区域的阵发性剧痛，其疼痛性质与三叉神经痛非常相似，可以分为原发性和继发性两大类。舌咽神经痛常发生在一侧舌根、咽喉、扁桃体、耳根部及下颌后部，有时以耳根部疼痛为主要表现[1-2]。该病的发病率低，约为三叉神经痛发病率的0.2%～1.3%。目前认为，该疾病的性别差异不大，大多在40岁以上发病。疼痛是该病严重影响患者生活质量的主要原因。该病首选药物治疗。近年来，经研究发现新型抗癫痫药物普瑞巴林能显著缓解各类神经性疼痛，并且不良反应少。本研究对我院门诊就诊的原发性舌咽神经癌患者采用普瑞巴林治疗舌咽神经痛，临床療效非常满意。现报道如下。

1 资料与方法

1.1 一般资料

选取2014年6月～2016年6月至宁波镇海龙赛医院口腔科门诊就诊的原发性舌咽神经痛患者。

入选标准：（1）具备典型的初次发病的原发性舌咽神经痛患者[3]；经体格检查并未发现神经系统阳性体征；……